Systemic Antimicrobials Consumption and Expenditures in Intensive Care Units of Hospitals in Russian Federation and Republic of Belarus: Results of Multicenter Pharmacoepidemiological Study | CMAC

Systemic Antimicrobials Consumption and Expenditures in Intensive Care Units of Hospitals in Russian Federation and Republic of Belarus: Results of Multicenter Pharmacoepidemiological Study

Clinical Microbiology and Antimicrobial Chemotherapy. 2014; 16(4):294-311

​ Belkova Yu.А., Rachina S.A., Kozlov R.S., Mischenko V.M., Pavlukov R.A., Kozlov S.N., Abubakirova A.I., Berezhanskiy B.V., Zubareva N.A., Karpov I.A., Palyutin Sh.H., Portnyagina U.S., Samuylo E.K.
intensive care unit ICU systemic antimicrobials consumption expenditures
Section
Pharmacoepidemiology
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2014; 16(4):294-311

Abstract

To assess systemic antimicrobials (AM) consumption and expenditures in intensive care units (ICU) of multiprofile hospitals in different regions of Russian Federation and Republic of Belarus in 2009–2010 retrospective collection of data from hospital expenditure notes was performed. AM consumption was calculated using ATC/DDD methodology and expressed in numbers of DDD/100 bed-days (DBD). Average AM consumption and expenditure rates in ICU in 2009 and 2010 were as follows: 122.5 DBD / 2.1 million rubles and 133.8 DBD / 2.4 million rubles; average cost of 1 DDD — 444.1 and 459.8 rubles, respectively. The highest consumption rates were for antibacterials for systemic use, J01 (97.6% in 2009 and 98.1% in 2010), such as non-penicillin beta-lactams, J01D (62.8% and 56.4%), other antibacterials, J01X, (12.4% and 13.6%, respectively), as well as quinolones, J01M, (12.4% in 2009) and aminoglycoside antibacterials, J01G, (10% in 2010); the highest expenditure rates — for antibacterials for systemic use, J01 (97.9% in 2009 and 98.4% in 2010), such as non-penicillin beta-lactams, J01D, (72.4% and 67.7%), other antibacterials, J01X, (13.9% and 8.5%, respectively), as well as quinolones, J01M, (6.7% in 2009) and aminoglycoside antibacterials, J01G, (7.7% in 2010). Improper AM consumption rates were unreasonably high (12.2% in 2009 and 11.1% in 2010) whereas improper expenditure rates were relatively low (2% and 1.4%, respectively). Study outputs can be used for budget allocation and AM distribution improvement in ICU as well as for development and efficacy control of local antimicrobial stewardship programs.

  • 1. Carlet J., Ben Ali A., Chalfine A. Epidemiology and control of antibiotic resistance in the intensive care unit. Curr Opin Infect Dis 2004; 17:309-16.
  • 2. Kollef M. H., Fraser V. J. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134:298-314.
  • 3. Esen S., Leblebicioglu H. Prevalence of nosocomial infections at intensive care units in Turkey: a multicentre 1-day point prevalence study. Scand J Infect Dis 2004; 36(2):144-8.
  • 4. Richards M. J., Edwards J.R., Culver D.H., Gaynes R.P. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27(5):887-92.
  • 5. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Surveillance Report, data summary from January 1996 through December 1997: a report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control 1999; 27:279-84.
  • 6. Centers for Disease Control and Prevention. Detailed ICU surveillance component: national nosocomial infection surveillance scheme 1-80. Atlanta, GA: Centers for Disease Control and Prevention, 1997.
  • 7. Руднов В.А., Бельский Д.В., Дехнич А.В., исследовательская группа РИОРИТа — Инфекции в ОРИТ России: результаты национального многоцентрового исследования. Клин микробиол антимикроб химиотер 2011; 13(4):294-303.
  • 8. Zarb P., Amadeo B., Muller A., et al. Identification of targets for quality improvement in antimicrobial prescribing: the web-based ESAC Point Prevalence Survey 200
  • 9. J Antimicrob Chemother 2011; 66(2):443-9. 9. Fridkin S. K., Steward C. D., Edwards J. R., et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999; 29(2):245-52.
  • 10. Meyer E., Schwab F., Gastmeier P., Rueden H., Daschner F.D. Surveillance of antimicrobial use and antimicrobial resistance in German intensive care units (SARI): a summary of the data from 2001 through 2004. Infection 2006; 34(6):303-9.
  • 11. Walther S.M., Erlandsson M., Burman L.G., et al. Antibiotic prescription practices, consumption and bacterial resistance in a cross section of Swedish intensive care units. Acta Anaesthesiol Scand 2002; 46(9):1075-81.
  • 12. Hanberger H., Arman D., Gill H., et al. Surveillance of microbial resistance in European Intensive Care Units: a first report from the Care-ICU programme for improved infection control. Intensive Care Med 2009; 35(1):91- 100.
  • 13. Паравина Е.В., Жестков А.В., Кулагин О.Л. Комплексный анализ и возможности оптимизации системной антимикробной терапии в многопрофильном стационаре. Известия Самарского научного центра Российской академии наук 2010;12(1):1865-70.
  • 14. Белькова Ю.А., Рачина С.А., Козлов Р.С. и соавт. Потребление и затраты на системные антимикробные препараты в многопрофильных стационарах Российской Федерации и Республики Беларусь: результаты многоцентрового фармакоэпидемиологического исследования. Клин микробиол антимикроб химиотер 2012; 14(4):322-41.
  • 15. Available from URL: www.whocc.no/atc_ddd_methodology/purpose_of_the_atc_ddd_system/
  • 16. World Health Organization. Introduction to Drug Utilization Research. 2003. Available from URL: www.whocc.no/filearchive/publications/drug_utilization_research.pdf
  • 17. Barenfanger J., Short M. A., Groesch A. A. Improved antimicrobial interventions have benefits. J Clin Microbiol 2001; 39:2823-8.
  • 18. Vincent J. — L. Nosocomial infections in adult intencivecare units. Lancet 2003; 361:2068-77.
  • 19. Stone P.W., Larson E., Kawar L.N. A systematic audit of economic evidence linking nosocomial infections and infection control interventions:1990-2000. Am J Infect Control 2002; 30:145-52.
  • 20. Vincent J.L., Rello J., Marshall J., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302(21):2323-9.
  • 21. Angus D. C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M. R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29(7):1303-10.
  • 22. Kollef M.N., Sherman G., Ward S., Fraser V. J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-74.
  • 23. Meyer E., Schwab F., Schroeren-Boersch B., Gastmeier P. Dramatic increase of third-generation cephalosporinresistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008. Crit Care 2010; 14(3): R113.
  • 24. Rogues A.M., Dumartin C., Amadéo B., et al. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect Control Hosp Epidemiol 2007; 28(12):1389-95.
  • 25. Jacoby T. S., Kuchenbecker R. S., Dos Santos R.P., Magedanz L., Guzatto P., Moreira L. B. Impact of hospital-wide infection rate, invasive procedures use and antimicrobial consumption on bacterial resistance inside an intensive care unit. J Hosp Infect 2010; 75(1):23-7.
  • 26. Thabet L., Memmi M., Turki A., Messadi A. A. The impact of fluoroquinolones use on antibiotic r sistance in an intensive care burn department. Tunis Med 2010; 88(10):696-9.
  • 27. Fridkin S.K., Edwards J.R., Courval J.M., et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 US adult intensive care unit. Ann Intern Med 2001; 135:175-83.
  • 28. Saurina G., Quale J.M., Manikal V.M., et al. Antimicrobial resistance in Enterobacteriacea in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns. J Antimicrob Chemother 2000; 45:895-8.
  • 29. Lautenbach E., Patel J.B., Bilker W.B., et al. Extended spectrum beta-lactamase-producing E. coli and K. pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162-71.
  • 30. Tacconelli E., De Angelis G., Cataldo M.A., et al. Does antibiotic exposure increase the risk of methicillinresistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 2008; 61:26-38.
  • 31. Zavascki A.P., Barth A.L., Gaspareto P.B., et al. Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-beta-lactamase in two tertiary-care teaching hospitals. J Antimicrob Chemother 2006; 58:882-5.
  • 32. Bassetti M., Righi E., Ansaldi F., et al. Impact of limited cephalosporin use on prevalence of methicillin-resistant Staphylococcus aureus in the intensive care unit. J Chemother 2009; 21(6):633-8.
  • 33. Yong M.K., Buising K.L., Cheng A.C., Thursky K.A. Improved susceptibility of Gram-negative bacteria in an intensive care unit following implementation of a computerized antibiotic decision support system. J Antimicrob Chemother 2010; 65(5):1062-9.
  • 34. Fridkin S.K., Lawton R., Edwards J.R., et al. Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Hospitals Emerg Infect Dis 2002; 8(7):702-7.
  • 35. Ananda-Rajah M.R., McBryde E.S., Buising K.L., et al. The role of general quality improvement measures in decreasing the burden of endemic MRSA in a medicalsurgical intensive care unit. Intensive Care Med 2010; 36(11):1890-8.
  • 36. Meyer E., Gastmeier P., Deja M., Schwab F. Antibiotic consumption and resistance: data from Europe and Germany. Int J Med Microbiol 2013; 303(6-7):388-95.
  • 37. Sukhorukova M., Kozyreva V., Ivanchik N., Edelstein M., Kozlov R., on behalf of the ROSNET Study Group. Five-year trends in the prevalence and types of ESBLs and antimicrobial susceptibility of ESBL-producing nosocomial strains of Enterobacteriaceae in Russia. Clinical Microbiology and Infection 2010; 16(Suppl. 2): S179.
  • 38. Неопубликованные результаты проекта МАРАФОН. НИИАХ, Смоленск, 2014.
  • 39. Skleenova E., Sukhorukova M., Timokhova A., et al. Sharp Increase in Carbapenem-Non-Susceptibility and Carbapenemase Production Rates in Nosocomial Gram-Negative Bacteria in Russia over the Last Decade. Proceedings of 53rd ICAAC; 2013 Sep 10-13; Denver, USA. C2-1092.
  • 40. Edelstein M.V., Skleenova E.N., Shevchenko O.V., et al. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect Dis 2013; 13(10):867-76.
  • 41. Fridkin S. K., Hill H. A., Volkova N. V. Intensive Care Antimicrobial Resistance Epidemiology Project Hospitals et al. Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis 2002; 8(7):697-701.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared